Last reviewed 2026-04-20 · How we verify

SB-659032

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Headache
• Urinary tract infection
• Nausea
• Dizziness
• Diarrhoea
• Cystitis

Key clinical trials

• A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease (PHASE2)
• Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers (PHASE1)
• An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks (PHASE2)
• Effect Of Rilapladib (SB-659032) On Platelet Aggregation (PHASE1)
• A Study to Assess the Effect of SB 659032 on Platelet Function (PHASE1)
• SB-659032 Platelet Aggregation Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.